AIM ImmunoTech (NYSEAM:AIM) Conference February 19, 2026 04:00 PM ET Company ParticipantsJenene Thomas - CEO and Investor Relations ContactThomas Equels - CEOJenene ThomasOkay, we are ready to get started. So good afternoon, and thank you for joining us for another Virtual Investor Closing Bell segment. Today, we are featuring AIM ImmunoTech. My name is Jenene Thomas. I am CEO of JTC IR, and I will be the moderator for today's event. I am very pleased to be joined by Thomas Equels. He is Chief Executive Off ...

At 7:05 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading high ...

Core Viewpoint - Falcon Oil & Gas Ltd. is set to cancel its admission to trading on AIM following a transaction with Tamboran Resources Corporation, which involves the issuance of shares and a cash payment to Falcon shareholders [2][3]. Transaction Details - The transaction includes Tamboran issuing 6,537,503 shares of its common stock to Falcon and a cash payment of $23,663,080 [3]. - Falcon shareholders, excluding dissenting shareholders or those subject to sanctions, will receive shares of Tamboran in exchange for their Falcon common shares [3]. Conditions for Completion - The completion of the transaction is contingent upon several approvals, including: - Approval from Falcon shareholders at a meeting scheduled for March 11, 2026 [4]. - Approval of the stock issuance by Tamboran stockholders [4]. - Approval of the plan of arrangement by the Supreme Court of British Columbia [4]. - No material adverse changes affecting either Falcon or Tamboran [4]. Timeline for AIM Cancellation - Falcon is required to provide at least 20 business days notice for the AIM Cancellation [5]. - If all conditions are met, the transaction is expected to close around March 16, 2026, with trading of Falcon's common shares on AIM suspended on March 17, 2026, and the cancellation effective on March 18, 2026 [5].

This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of the Rights Offering. OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatoli ...

Core Viewpoint - AIM ImmunoTech is set to present its lead program, Ampligen, for the treatment of pancreatic cancer during a virtual investor event on February 19, 2026, highlighting its clinical and regulatory strategy [1][2]. Group 1: Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on developing Ampligen (rintatolimod) for late-stage pancreatic cancer, addressing a significant global health issue [4]. - Ampligen is characterized as a dsRNA and highly selective TLR3 agonist immuno-modulator, demonstrating broad-spectrum activity in clinical trials [4]. Group 2: Event Details - Thomas K. Equels, the CEO of AIM, will participate in a Virtual Investor Closing Bell Event on February 19, 2026, at 4:00 PM ET [1]. - The event will emphasize the ongoing DURIPANC clinical trial, which involves a collaboration with AstraZeneca, combining Ampligen with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, Imfinzi (durvalumab), for treating metastatic pancreatic cancer [2]. - A live video webcast of the presentation will be available on the company's website, with a replay accessible for 90 days after the event [3].

AIM ImmunoTech Conference Summary Company Overview - AIM ImmunoTech is a late-stage immunopharma company focused on the drug Ampligen (rintatolimod), which has shown efficacy and safety in various solid tumors, particularly in oncology since its repurposing from chronic fatigue syndrome in 2016-2017 [1][2] Core Points and Arguments - **Pancreatic Cancer Focus**: The company is prioritizing the approval of Ampligen for pancreatic cancer, having initiated a program in 2017 with a Dutch government-approved early access program for late-stage patients [2][4] - **Clinical Trials**: Currently conducting a Phase I-II trial combining Ampligen with AstraZeneca's Imfinzi (durvalumab) at Erasmus Medical Center, with approximately 75 subjects treated so far [2][6] - **Mechanism of Action**: Ampligen is described as converting "cold tumors" into "hot tumors" by altering the tumor microenvironment, specifically the ratio of suppressor T cells to killer T cells [3][4] - **Safety Profile**: The drug has a well-established safety profile with over 100,000 IV doses administered, and approvals for various administration methods [4][5] - **Market Opportunity**: The company sees a significant opportunity in the pancreatic cancer market, supported by patent and orphan drug designations that provide market exclusivity [5][6] Key Data and Results - **Survival Benefits**: In the early access program, the median overall survival for 57 subjects was 19.7 months, compared to 12.5 months for the standard of care, resulting in an 8.6-month survival benefit [8][17] - **Quality of Life**: Patients reported significant improvements in quality of life, which is crucial given the poor quality of life associated with late-stage pancreatic cancer [8][19] - **Immunological Markers**: Specific biomarkers, such as the neutrophil-lymphocyte ratio and CA19-9 levels, have been identified as predictive of Ampligen's response and overall survival [9][10] Future Milestones - **DURIPANC Program**: The program aims to treat 25 subjects, with 18 currently in treatment. The last subject is expected to be treated by the end of the year, which will be a significant milestone [20][21] - **Phase III Trial Planning**: The company is already planning for a Phase III trial, with the goal of demonstrating continued positive impacts on survival and quality of life [21][22] Additional Important Information - **Patent Protection**: A recent U.S. patent covering Ampligen in combination with PD-L1 for various cancers is valid until 2039, enhancing the company's market position [5][6] - **Orphan Drug Designation**: This designation provides up to 10 years of market protection in the EU, commencing upon drug approval, which is critical for the company's strategy [6][7] This summary encapsulates the key points from the AIM ImmunoTech conference, highlighting the company's focus on pancreatic cancer, the efficacy and safety of Ampligen, and the strategic planning for future clinical trials and market opportunities.

Core Viewpoint - AIM ImmunoTech Inc. has initiated a rights offering to raise funds for the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, a significant global health issue [1][10] Rights Offering Details - The rights offering allows holders of the Company's common stock and certain options and warrants to purchase up to 12,000 units at a subscription price of $1,000 per unit [2][4] - Each subscription right entitles the holder to purchase one unit, which consists of one share of Series G Convertible Preferred Stock and 1,666 warrants to purchase common stock [3] - The preferred stock is convertible into 833 shares of common stock at a conversion price of $1.20 per share, and each warrant is exercisable for one share of common stock at the same exercise price [3] Financial Projections - If fully subscribed, the rights offering is expected to generate gross proceeds of $12 million [4] - Holders who fully exercise their basic subscription rights can subscribe for additional units that remain unsubscribed [4] Subscription Period - The subscription period commenced on February 11, 2026, and will end on February 27, 2026, unless extended by the Company [5] - Subscription rights are non-transferable and must be exercised during the subscription period [5] Management and Regulatory Information - Maxim Group LLC has been engaged as the dealer-manager for the rights offering [6] - The offering is made pursuant to a registration statement declared effective by the SEC on February 10, 2026 [7]

As filed with the Securities and Exchange Commission on February 10, 2026 Registration No. 333-292085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIM ImmunoTech Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 52-0845822 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Nu ...

Core Perspective - The company has announced the signing of a definitive agreement for the sale of Bozzetto, indicating a strategic move to optimize its portfolio and focus on core operations [2]. Transaction Overview - The transaction is positioned as a significant step for the company, with plans to review upcoming timelines and the intended use of proceeds from the sale [2]. - The call includes participation from key executives, highlighting the importance of the transaction to the company's leadership [3]. Communication and Information - A presentation will be utilized during the call, and it is available on the company's Investor Relations website for stakeholders [3]. - The company acknowledges that some statements made during the call may be forward-looking, which could lead to future results differing from current discussions [3][4].

Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [3] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, showing broad spectrum activity in clinical trials [3] Upcoming Event - AIM will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026 [1] - Thomas K. Equels, the CEO of AIM, will provide a corporate overview and business outlook, with a focus on the company's strategic emphasis on pancreatic cancer [1] - The presentation is scheduled for February 11, 2026, at 1:40 PM EST [1]